Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 16.7% during trading on Friday . The company traded as low as C$0.08 and last traded at C$0.08. 405,500 shares traded hands during mid-day trading, an increase of 4% from the average session volume of 389,087 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Performance
The stock has a market capitalization of C$11.66 million, a price-to-earnings ratio of -2.33 and a beta of 0.20. The stock has a 50-day moving average of C$0.12 and a 200 day moving average of C$0.13. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Energy Stocks to Gain Exposure to the Carbon Capture Boom
- Following Congress Stock Trades
- AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- The Real Reason Ford Stock Is Rallying—Can It Keep Going?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
